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ABSTRACT
Epidemiological and preclinical studies propose that metformin, a first-line drug 
for type-2 diabetes, exerts direct antitumor activity. Although several clinical trials 
are ongoing, the molecular mechanisms of this effect are unknown. 
Here we show that chloride intracellular channel-1 (CLIC1) is a direct target of 
metformin in human glioblastoma cells. Metformin exposure induces antiproliferative 
effects in cancer stem cell-enriched cultures, isolated from three individual WHO grade 
IV human glioblastomas. These effects phenocopy metformin-mediated inhibition of a 
chloride current specifically dependent on CLIC1 functional activity. CLIC1 ion channel 
is preferentially active during the G1-S transition via transient membrane insertion. 
Metformin inhibition of CLIC1 activity induces G1 arrest of glioblastoma stem cells. 
This effect was time-dependent, and prolonged treatments caused antiproliferative 
effects also for low, clinically significant, metformin concentrations. Furthermore, 
substitution of Arg29 in the putative CLIC1 pore region impairs metformin modulation 
of channel activity. 
The lack of drugs affecting cancer stem cell viability is the main cause of 
therapy failure and tumor relapse. We identified CLIC1 not only as a modulator of 
cell cycle progression in human glioblastoma stem cells but also as the main target 
of metformin’s antiproliferative activity, paving the way for novel and needed 
pharmacological approaches to glioblastoma treatment.
INTRODUCTION
Epidemiological studies reported that metformin, a 
first-line treatment for type-2 diabetes [1], is associated 
with reduced incidence and favorable prognosis in several 
cancers [2-4]. Moreover, metformin directly inhibits 
cancer cell proliferation, mainly acting on cancer stem 
cells (CSCs) [5-10]. On these bases, several clinical trials 
are underway [4, 11]. 
Although metformin was clinically approved 
several decades ago, its mechanism of action has not 
been completely elucidated. Metformin metabolic effects 
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mainly rely on mitochondrial activity: it decreases ATP 
production and activates AMP-activated protein kinase 
(AMPK), thus regulating gluconeogenesis and fatty acid 
synthesis [12]. Since AMPK controls mammalian target 
of rapamycin (mTOR) activity, metformin’s regulation of 
AMPK could also account for its antiproliferative effects 
[13, 14]. 
However, several lines of evidence suggest that 
this is not the case. If metformin merely acted as mTOR 
inhibitor, it should induce the same tumor resistance 
mechanisms as “classical” mTOR blockers (i.e. 
rapamycin), such as the relief of the mTOR/S6K1 negative 
feedback loop on IGFR-1/IRS-1, the activation of receptor 
tyrosine kinase-mediated intracellular pathways [15] and 
the loss of antiproliferative activity [16]. In contrast, 
epidemiological and preclinical studies suggest that 
metformin has long-term antiproliferative effects. Further, 
in CSCs isolated from breast and lung carcinomas, or 
glioblastoma (GBM) [8, 9, 17-21], metformin-dependent 
cell proliferation arrest does not involve AMPK, but rather 
the down-regulation of IGF-1 signaling or inhibition of 
Akt [17, 22, 23]. Conversely, the synthetic AMPK agonist 
A-769662 provided a proliferative advantage to the 
cells [21]. On the other hand, metformin was reported to 
affect several other intracellular pathways in tumor cells, 
including HER1/HER2, Src, S6K1, c-MYC, and STAT3 
among others [16, 24-27], being also able to overcome 
dietary restriction-resistance in cancer cells [28]. 
The heterogeneity of the reported mechanisms 
of action could imply that metformin is a promiscuous 
drug, rather than acting on precise pathways. Conversely, 
the broad range of tumors affected by metformin might 
suggest that, instead of modulating different pathways in 
each cancer histotype, an upstream target could represent 
its specific mechanism of action. 
In this context, our study aims to identify the 
molecular mechanism by which metformin specifically 
elicits antitumoral effects without interfering with normal 
cell viability.
Chloride intracellular channel 1 (CLIC1) [29-31] is 
involved in development of the most aggressive human 
tumors, including GBMs [32-34]. In resting cells, CLIC1 
is mainly localized in the cytosol, but it is progressively 
oxidized during cell cycle progression, and transiently 
recruited to the plasma-membrane, where it functions 
as a chloride selective ion channel [35, 36]. In vivo and 
in vitro proliferation of GBM CSCs depends on CLIC1 
activity and its inhibition reduces tumor development in 
animal models [32], thus, CLIC1 could be a target for 
antiproliferative molecules. 
Importantly, in vivo studies already demonstrated 
that CLIC1 is required for GBM tumorigenesis [32], 
and that metformin treatment of mice orthotopically 
xenografted with human GBM CSCs, reduced tumor 
growth [18], confirming the more copious in vitro results.
On these premises, the goal of this study was to 
determine whether CLIC1 is involved in metformin 
inhibition of GBM cell proliferation. 
RESULTS
Correlation between CLIC1 inhibition and 
antiproliferative effect of metformin in 
glioblastoma cells
Metformin effects were initially tested in U87 
human GBM cell line. We measured the effects of IAA94, 
a well-characterized CLIC1 inhibitor [31], prior or 
subsequently to the addition of metformin, in perforated 
patch clamp whole-cell configuration experiments. In 
both cases, the first compound decreased the whole cell 
current that was not further reduced by the second one 
(Fig. 1A and B). Current/voltage (I/Vs) relationships (Fig. 
1C and D) show that the current amplitudes, at different 
membrane potentials, are superimposed, suggesting that 
the two drugs converge on the same molecular target (Fig. 
S1). Metformin EC
50
, as CLIC1 inhibitor, was 2.1mM 
(Fig. 1E), while IAA94 showed EC
50
 (32µM, Fig. S1D) 
similar to previous reports [31].
Outside-out single-channel recordings confirmed 
CLIC1 as metformin target on U87 membranes, where 
CLIC1 retains single-channel properties, previously 
described for outside-out experiments (Fig. S2A and B) 
[29]. Metformin perfusion (Fig. 1F, arrow) efficiently 
inhibits single channel activity, showing a current 
inhibition that lasted for several minutes after wash-
out, being practically irreversible (Fig. S2C), and highly 
specific for CLIC1, since 4,4’-diisothiocyanatostilbene-
2,2’-disulphonic acid (DIDS)-sensitive chloride channels 
were unaffected (Fig. S2D). 
Inhibition of CLIC1 current by metformin or 
IAA94 was associated with time- and dose-dependent 
decrease of U87 cell viability, showing maximal efficacy 
after 72 hours of treatment (MTT assay; Fig. 1G and 
H, Table 1). EC
50 
values (1.7mM for metformin and 
40.5µM for IAA94) are comparable to those obtained in 
electrophysiology experiments (see above), suggesting 
that the inhibition of CLIC1 activity and the reduction 
of cell viability are related events. Metformin efficacy 
as antiproliferative agent was also time-dependent since 
longer exposure to the drug required lower metformin 
concentrations to elicit antitumoral effects (EC
50
: 23, 6.6 
and 1.7mM after 24, 48 and 72 hours).
CLIC1 involvement in metformin antiproliferative 
effects in human glioblastoma cancer stem cells
GBM CSC-enriched cultures better reproduce in 
vitro, the biological and pharmacological in vivo behavior 
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of tumor cells than established cell lines [37, 38]. We 
isolated CSCs from three human GBMs, to test the role 
of CLIC1 in the antiproliferative effects of metformin. 
These cells were either grown in stem cell-permissive 
medium [39] retaining CSC-like features (clonogenicity, 
stem cell marker expression, and in vivo tumorigenicity), 
or shifted for 14-days in FBS-containing medium to 
induce differentiation (Fig. S3A). Differentiation was 
demonstrated by increased expression of astrocytic 
(GFAP: Fig. 2A and B, and Fig. S4C and E) and neuronal 
(βIII-tubulin: Fig. S3B and C) markers, and the parallel 
down-regulation of stem cell makers (Nestin, Olig2, and 
Sox2: Fig. S3B and C). 
CLIC1 was highly expressed in CSC cultures, 
but its protein levels were highly down-regulated after 
differentiation (Fig. 2A and B, and Fig. S4A, B, C and D). 
Metformin dose-dependently reduced CSC viability (EC
50
: 
3.9, 11.3, and 8.0mM for GBM1-3, respectively, after 48 
hours of treatment), but failed to induce cytotoxicity in 
differentiated cells (Fig. 2C, and Fig. S4F) that resulted 
statistically significant only at highest concentration 
(40mM), reaching a maximal inhibition <30%, while the 
same concentrations almost completely suppress CSC 
viability (-76-86% ) (Fig. 2C and Fig. S4F). Similar results 
were obtained blocking CLIC1 activity using IAA94 (Fig. 
2D, and Fig. S4G). The analysis of DNA synthesis, by 
BrdU incorporation assay, confirmed the antiproliferative 
activity on CSC by both metformin and IAA94 (Fig. 2E 
and F).
The correlation between metformin’s inhibition 
of CSC proliferation and CLIC1 functioning, was 
corroborated by electrophysiological measurements of 
metformin-sensitive CLIC1 current densities that were 
negligible in differentiated cells as compared to CSCs 
(Fig. 2G, H, I and L). 
Fig. 1: Metformin decreases U87 cell viability via CLIC1 
inhibition. A) Representative family of membrane currents 
elicited by 800 ms voltage steps from -100 to +80 mV, starting 
from a holding potential of -40 mV, is shown in the control 
condition (top), after perfusion of IAA94 (100µM, middle) and 
after addition of metformin (10mM, bottom) and vice versa (B). 
C) Current/voltage relationships from the data in A, in which 
IAA94 is perfused alone or followed by metformin, and vice 
versa (D). Total current (triangles) is plotted together with the 
current amplitude after IAA94 (circles) perfusion or IAA94 and 
metformin (squares). E) The ratio between metformin and IAA94 
sensitive currents (+80 mV, 750 ms test potential) was used to 
calculate a metformin EC
50
 of 2.1 ± 0.4 mM (mean ± s.e.m.) from 
a dose/response plot. (n=4 independent experiments for each 
concentration). F) Ten mM metformin (arrow) caused inhibition 
of CLIC1 single-channel opening in outside-out experiments, 
recorded at +60 mV holding potential (single channel in control 
conditions Popen= 0.36±0.012, 0.28±0.08 and 0.09±0.07 between 
5 and 10 and 10 and 15 seconds after metformin addition, 
respectively; n=3 total of 4 minutes continuous recording). G-H) 
Time- and dose-dependent effects of metformin and IAA94 on 
U87 cell survival evaluated by MTT assay. Experiments were 
run in quadruplicate and the percentage of inhibition calculated 
against vehicle control. Data are expressed as mean ± s.e.m of 
n=3 independent experiments. Statistical significance is reported 
in Table 1.
Table 1: Statistical significance of time- and dose-dependent effects of metformin and IAA94 on U87 cell survival
Time Metformin (mM) IAA94 (µM)
1 3 10 30 50 1 10 30 100 300
24h n.s. n.s. n.s. <0.0001 <0.0001 n.s. n.s. n.s. <0.0001 <0.0001
48h <0.05 <0.0001 <0.0001 <0.0001 <0.0001 n.s. n.s. n.s. <0.0001 <0.0001
72h <0.0005 <0.0001 <0.0001 <0.0001 <0.0001 n.s. n.s. n.s. <0.0001 <0.0001
Data are obtained comparing treated cell viability with vehicle-treated control cells, in MTT assay.
One-way ANOVA, followed by Dunnett’s post hoc test.
n.s.: not significant.
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Fig. 2: Metformin reduces human GBM CSC viability via inhibition of CLIC1 current. A) Representative expression of CLIC1 
and GFAP in GBM1 CSC-enriched and differentiated cell cultures, obtained shifting CSCs from growth factor-supplemented to growth 
factor-free and FBS-containing medium. CLIC1 expression is reduced in differentiated cells, which conversely show increased GFAP 
expression. Similar results are obtained in GBM 2 and 3 (Fig. S4). RP = recombinant CLIC1 protein (positive control). B) Quantification 
of the data in A, by densitometry, averaging replica Western blots (n=3). An inverse modulation of CLIC1 and GFAP expression occurs 
after GBM1 cell differentiation. Band intensities were normalized to the corresponding α-tubulin signal and expressed as arbitrary units 
(A.U.) referred to CSC protein levels (assumed as 1). **p<0.01; ***p<0.001 (t-test). C) Metformin dose-response curves (1-40mM) on 
GBM1 CSC (filled circles) and differentiated (empty circles) cell viability, measured by MTT assay. Experiments, were performed in 
quadruplicate (n=3); percentage of inhibition was calculated vs. vehicle-treated controls. A significant cell viability reduction was observed 
in CSCs (**p<0.01 and ***p<0.001 vs. controls, one-way ANOVA, followed by Dunnett’s test). In differentiated cells a modest effect 
was observed (**p<0.01 vs. controls). At all concentrations, metformin effects on CSCs were statistically different from those induced in 
differentiated cells (°p<0.05, °°p<0.01, °°°p<0.001 vs. differentiated cells; one-way ANOVA, Tukey’s test). Dotted line represents vehicle-
treated control values. D) Dose-response effects of IAA94 (1-300µM) on viability of GBM1 CSC (filled circles) and differentiated (empty 
circles) cells, measured by MTT assays. Experiments were run in quadruplicate, and the percentage of inhibition was calculated against 
vehicle controls (n=3). A significant inhibition of cell viability was observed. (**p<0.01 and ***p<0.001 vs. controls, one-way ANOVA, 
followed by Dunnett’s test), while differentiated cells were not affected. IAA94 effects on CSCs were also statistically different from 
those observed in differentiated cells (°p<0.05, °°°p<0.001 vs. differentiated cells; one-way ANOVA, followed by Tukey’s test). Dotted 
line represents the respective vehicle-treated control values. E) Metformin (1-30mM) inhibition of DNA synthesis in GBM 1-3 CSCs, 
measured by BrdU incorporation assay. A significant reduction of DNA synthesis was observed after 24 hours of treatment of randomly 
cycling CSCs (**p<0.01 and ***p<0.001, vs. respective controls; one-way ANOVA, followed by Dunnett’s test). Dotted line represents 
vehicle-treated control values. F) IAA94 (100 µM) inhibits DNA synthesis in GBM 1-3 CSCs, measured by BrdU incorporation assay. A 
significant reduction in DNA synthesis was observed after 24 hours of treatment of randomly cycling CSCs (*p<0.05 and **p<0.01 vs. 
respective controls, one-way ANOVA, followed by Dunnett’s test). G-H) Comparison of metformin-sensitive membrane current recorded 
in perforated patch experiments, elicited by 20 mV and 800 ms voltage steps from -40 mV holding potential to +60 mV in CSC (G) 
and differentiated (H) GBM1 cells. I-L) Cell capacitance measurements (n=10, GBM1 CSCs mean=6.52+/-0.92; GBM1 differentiated 
cells mean=69.56+/-6.46, ***p<0.001, t-test) (I), were instrumental to obtain membrane current densities (n=5, mean ± s.e.m. from 5 
independent experiments (L). While differentiated cells show a 10-fold larger membrane extension, they have one-third of the metformin-
sensitive current density compared to CSCs (p<0.001, t-test). 
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We knocked-down CLIC1 expression in CSCs by 
specific shRNA lentiviral infection (shCLIC1), verified by 
immunocytofluorescence (Fig. 3A) and Western blot (Fig. 
3B). Metformin inhibited CLIC1 conductance in wt GBM1 
CSCs with an EC
50
 (2.3mM) similar to U87 cells (Fig. 
3C). Both IAA94 and metformin reduced CLIC1 current 
in control (shLuc)-infected CSCs, while CLIC1-silenced 
CSCs showed lack of ionic flow (Fig. 3D). Current/voltage 
relationships (Fig. 3E) show, in an average of several 
cells, a consistent CLIC1 current in shLuc control cells 
(open circles), while in CLIC1-silenced CSCs the average 
metformin and IAA94 sensitive currents (open squares) 
decline by more than 50%. Furthermore, shCLIC1-CSCs 
show lower metformin (and IAA94) cytotoxicity (Fig. 
3F), confirming, at molecular level, that CLIC1 mediates 
metformin’s antiproliferative effects.
The specificity of metformin antiproliferative effects 
towards CSCs [17, 18] was showed demonstrating that 
metformin (and IAA94) did not affect human umbilical 
cord-derived mesenchymal stem cell (ucMSC) viability 
(Fig. 4A), in agreement with previous studies in which 
metformin was reported to exert a trophic activity for 
adult stem cells [40]. Differently from GBM CSCs, CLIC1 
was not detected in the ucMSC membrane compartment, 
where it acts as ion channel, but was confined as inactive 
protein within the cytosol (Fig. 4B and C), thus CLIC1 
Fig. 3: CLIC1 silencing increases human GBM CSC 
survival in the presence of metformin.  A and B) GBM1 CSCs 
were transiently infected with a plasmid carrying validated 
shRNA for both Luciferase (shLuc, as a silencing control) 
and CLIC1 (shCLIC1) and tested for CLIC1 expression. In 
shCLIC1 cells, protein levels were highly reduced as assessed 
by immunocytofluorescence (A, shRNA= green, CLIC1= red) 
and Western blot analysis (B). Reported blot is representative 
of 2 independent experiments. C) Metformin inhibition of 
CLIC1 current in GBM1 CSCs. Dose-response of metformin 
sensitive current experiments expressed as a percentage of 
maximal inhibition operated by 100 µM IAA94 (n=3 for 0.1-
5-20 mM, n=6 for 1 mM, n=4 for 10 mM), an EC
50
 of 2.3 
mM. D) Perforated patch whole-cell experiments using a 
voltage protocol of 800 ms, 20 mV steps from -60 to +60 mV, 
starting from -40 mV holding potential. Left panels depict 
IAA94- and metformin-sensitive currents in shLuc cells. In 
shCLIC1-transfected cells (right panels), the current that results 
sensitive to either metformin or IAA94 treatment is null. E) I/V 
relationships of metformin (left panel) and IAA94 (right panel) 
sensitive current densities of shLuc (circle; n=7 for metformin; 
n=4 for IAA94) and shCLIC1 (squares; n=6 for metformin; n=4 
for IAA94). Data are expressed as mean ± sem cells. F and G) 
Down-regulation of CLIC1 expression slightly affects basal cell 
proliferation (-14% at 48 hours vs. shLuc cells) but significantly 
reduces the effects of metformin and IAA94 on CSC viability 
after 48 hours of treatment, evaluated by MTT assay. Results 
demonstrate that the expression of CLIC1 is required for the 
antiproliferative activity of metformin in GBM CSCs. Dotted 
line represents the respective untreated control value for shLuc 
and shCLIC1 infected cells, taken as 100%. *p<0.05, **p< 0.01 
and ***p<0.0001 (t-test).
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current was negligible (Fig. 4D). These results suggest 
that metformin inhibits proliferation only in cells in which 
CLIC1 functioning is required for proliferation (i.e. GBM 
CSCs) [32], but it spares normal stem cells although these 
cells retain CLIC1 expression.
Inhibition of G1-S transition as metformin’s 
antiproliferative mechanism
CLIC1 translocates to the membrane following 
an increase in cytosolic oxidative state [35, 41, 42] 
corresponding to a peak of ROS during G1-S transition 
[43]. Thus, CSCs were synchronized by growth factor 
starvation (60 hours), to accumulate cells in G0/G1, and 
nocodazole/cytochalasin B treatment, to freeze cells in 
G2/M, and cell cycle evaluated by FACS. After the relief of 
cell cycle arrest and administration of metformin, IAA94, 
or vehicle (Fig. 5A), randomly cycling cells showed a 
partial arrest in G1, 24 hours after metformin or IAA94 
treatment, consistent with DNA synthesis experiments 
(Fig. 2E and F). Release of G0/G1 synchronized cells 
(about 92% of cells in G0/G1) allowed a synchronous re-
entry in the cell cycle, mostly evident after 24 hours, that 
was abolished in the presence of metformin or IAA94. 
Finally, cells released from nocodazole treatment (55% 
of cells in G2/M) after 6 hours progressed to G1 in the 
presence of metformin and IAA94, similarly to untreated 
cells. However, after 24 hours, while untreated cells 
continued to S phase, almost 80% of metformin/IAA94-
treated cells were blocked in G1 (Fig. 5A). The G1-S 
transition is therefore the target of both metformin and 
IAA94’s antiproliferative effects. Consistently, 24 hour 
treatment with metformin (or IAA94) of randomly cycling 
GBM CSCs, decreased both retinoblastoma protein (Rb) 
content and its phosphorylation status (Fig. 5B).
Fig. 4: Effects of metformin and IAA94 on umbilical cord-derived mesenchymal stem cells (ucMSCs) viability. A) Metformin 
(1-40mM) and IAA94 (1-100µM) for 48 hours failed to reduce ucMSCs viability, measured by MTT assay, performed in quadruplicate 
(n=3). B) CLIC1 expression in ucMSCs measured by immunofluorescence. Phalloidin staining (red) highlights cell shape, while indirect 
immunofluorescence identifies CLIC1 (green). C) Differential CLIC1 expression in ucMSCs and GBM1 CSCs evaluated by Western 
blotting, in cytosolic and plasma membrane fractions. N-cadherin and α-tubulin expression, used to normalize for membrane and cytosolic 
proteins, respectively, confirmed the lack of significant protein contamination between cell fractions. Representative blots are reported 
(n=2). D) IAA94-sensitive current in ucMSCs and GBM1 CSCs. The plot shows the current/voltage relationship of perforated patch whole-
cell experiments. IAA94-sensitive current measurement demonstrated that ucMSCs (squares) have negligible CLIC1 membrane current, 
compared to CSCs (circles). 
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Fig. 5: Metformin causes GBM CSC arrest in the G1 phase of the cell cycle. A) GBM1-derived CSCs were evaluated by FACS 
analysis for cell cycle progression after propidium iodide staining (n=2). Control, metformin (10 mM)- or IAA94 (100 µM)-treated cells 
were analysed after 6 and 24 hours without synchronisation (randomly cycling, upper panels), after G0/G1 arrest (induced by 60 hours of 
growth factor deprivation, middle panels) or after blockade induced by nocodazole/cytochalasin B treatment (overnight incubation with 
50 ng/mL nocodazole + 25 ng/mL cytochalasin B, lower panels). At experimental time 0 (depicted in the original histograms from the 
FACS on the left, and in the first superimposed bars), randomly cycling cells show the following cell cycle distribution: G0/G1= 59.25%; 
S=33.75%; G2/M=7%; starvation induced a clear G0/G1 synchronisation (91.88% of the cells, with only 5.12 and 3% in phase S and G2/M, 
respectively); nocodazole treatment caused cell accumulation in G2/M (55.49%) with 29.64% of the cells in G0/G1 and 14.87% in S phase. 
Cells were subsequently shifted into standard growth factor-containing CSC medium and allowed to grow for 6 or 24 hours. Treatment 
with both metformin and IAA94 caused a strong reduction of cell cycle progression that was mainly due to the blockade of G1-S transition. 
B) Western blot analysis of retinoblastoma (Rb) protein in metformin- and IAA94-treated CSCs.  Metformin (10 mM) and IAA94 (100 
µM) affects Rb protein expression and phosphorylation status in GBM1 CSCs. Treatment with either drug not only drastically reduced Rb 
protein content, but also led to a higher prevalence of non-phosphorylated protein in treated cell extracts compared to control conditions. 
Thus, metformin- and IAA94-induced cell cycle arrest correlates with a reduction of Rb content and a shift towards the non-phosphorylated 
form. Representative Western blot is reported in the left panel, and the quantification by densitometric analysis of two replica experiments 
is depicted in the right panel (***p<0.001, t-test).
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Metformin inhibition of CLIC1 is use-dependent 
and it is lost in CLIC1 mutants lacking Arg29 
within the channel pore 
The direct metformin interaction with CLIC1 was 
tested in CHO cells transfected with wild type (wt) and 
mutant CLIC1. In CLIC1 wt-transfected cells, whole-cell 
electrophysiology recordings show a slow (few minutes) 
metformin inhibition of chloride current (Fig. 6A and B), 
similar to what observed in GBM cells. This kinetics was 
explained as an activity-dependent inhibition of CLIC1 
current due to a direct interaction with the channel. Indeed, 
CLIC1 inhibition by metformin was dependent on the 
frequency of stimulation (Fig. 6C, D and E), suggesting 
that metformin binds CLIC1 only in the open state. 
In this and previous reports, metformin antitumor 
effects occur at concentrations in the millimolar range (1-
50mM) [8, 9, 25, 44]. Such high concentrations however, 
although referred as “oncobiguanides” treatments [45], 
were often questioned as far as the in vivo significance 
of these effects. Nevertheless, the lack of toxicity in 
differentiated GBM cells and in ucMSCs, as demonstrated 
in our study, argues against a non-specific in vitro 
effect. In addition, prolonged treatment with equimolar 
concentration of arginine did not reduce CSC viability 
(Fig. S5), indirectly confirming that the observed effects 
are specific for metformin.
Fig. 6: CLIC1 current inhibition by metformin is use-
dependent. A) Time-course of whole-cell currents in CHO 
cells transfected with human wt CLIC1, and stimulated every 5 
seconds with 800 ms, 100 mV test potential from -40 mV holding 
voltage. Each point represents the average current of the last 100 
ms of a single current trace. Once the current amplitude reached 
a constant value, the cell was challenged with 10mM metformin. 
At a new steady-state the cell was perfused with 100µM IAA94 
that was used to completely block CLIC1 conductance. B) Dose-
response curve built perfusing cells with different metformin 
concentrations (0.05-50 mM) followed by IAA94 (100µM). 
Each point is the average result of 5 measurements. C) Examples 
of metformin (10mM) inhibition kinetics in three different 
experiments in which cells were stimulated with voltage steps 
delivered every 10, 5 or 2.5 seconds. D-E) Negative slope 
portions of several experiments, as in panel C, at different 
stimulation frequencies were normalised as percentages of 
the maximum current value of each trial. Average inhibition 
time-courses at stimulation frequencies 0.1 (squares; n=7), 0.2 
(circles; n=9), and 0.4 Hz (triangles; n=8) were plotted and fitted 
with a linear regression function (D). Calculated slopes of the 
average inhibition of time-course currents (0.1 Hz= -0.231±0.01; 
0.2 Hz= -0.577±0.01; 0.4 Hz= -1.052±0.02) are coincident 
with the average result obtained by plotting single-experiment 
metformin inhibitory slopes in a box-plot (E). Higher frequency 
stimulation induces faster inhibition of the current. The 
difference between 0.1 and 0.2 Hz is not statistically significant 
(p=0.12), but stimuli at 0.4 Hz are significantly different from 
slower stimulation frequencies (**p <0.001, ***p <0.0001, 
one-way ANOVA, followed by Tukey test). F) Representative 
metformin-sensitive membrane current time-course of perforate 
whole-cell patch clamp experiment in GBM CSCs, at high 
frequency stimulation. Voltage step (100 mV, 400 ms) from -40 
to +60 mV of membrane potential was delivered every second 
(1 Hz). Once the membrane current amplitude was stabilized, 
metformin was perfused during continuous stimulation. In all 
cases membrane current decreases but was not further inhibited 
by IAA94 (100µM). G) Ratio between metformin and IAA94-
sensitive current in the different conditions reported (n=3). H) 
CSC viability measured by MTT assay after 7 (black line), 10 
(dark grey) or 15 (light grey) days of metformin treatment (n=2; 
*p<0.05, **p< 0.01 and ***p<0.0001, t-test vs. vehicle-treated 
cultures).
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Importantly, our data provide a mechanistic 
interpretation for the apparent incongruence between 
in vitro effective concentrations and in vivo achievable 
drug levels. According to our results (Fig. 4), metformin 
acts only when CLIC1 is active in the membrane. Given 
the short timing of channel activity, the limited number 
of CLIC1 molecules present on the membrane, and the 
relatively low open channel probability [41], the chance 
to find an open CLIC1 channel in the membrane during 
the G1-S transition is very low. In acute electrophysiology 
experiments or short-time cell viability experiments, being 
CLIC1 inhibition by metformin practically irreversible, 
only high concentrations of metformin (i.e. 10mM) can 
inhibit a significant percentage of active channels to obtain 
inhibition of cell proliferation. Thus, the antiproliferative 
effects are not only strongly dependent on metformin 
concentrations but also on the duration of treatment, 
considering that in clinical trials prolonged (weeks or 
months) in vivo treatments are performed [46].
Accordingly, high frequency stimulation (in which 
more open channels are simultaneously available to 
metformin) or longer exposure to the drug (in which a 
prolonged inhibition progressively blocks the activity 
of all CLIC1 pools that reach cell membrane during cell 
Fig. 7. CLIC1 point mutation impairs metformin effects. 
A) Whole-cell current time-course of CHO cells transfected 
with CLIC1-wt, stimulated every 5 seconds with 800 ms, 100 
mV test potential from -40 mV holding voltage. Metformin 
(10mM) inhibits membrane current, which was not further 
decreased by IAA94 (100µM). B) Similar experiments as in 
A, using CHO cells transfected with CLIC1 R29A show that 
metformin (10mM) achieves only a partial block of IAA94 
(100µM)-sensitive current. C) Representative dose-response 
curves of IAA94-dependent current inhibition demonstrate that 
both CLIC1 constructs transfected in CHO cells have a similar 
EC
50 
: 27.3 µM for CLIC1-wt (squares, n=4, data expressed as 
mean±s.e.m.), and 29.2 µM for CLIC1-R29A (circles, n=4). 
Data are reported as inhibition of IAA94-sensitive current, 
over maximal inhibition. D) Box-plot quantifying metformin-
insensitive portion of IAA94-sensitive current. Ratio between 
metformin (10mM) and IAA94 (100µM) is reported for native 
CHO cells (n=4, mean 0.83±0.06), cells transfected (Tx) with 
CLIC1-wt (n=8, mean 0.83±0.03), CLIC1-R29A (n=9, mean 
0.54±0.06) and CLIC1 K37A (n=5, mean 0.87±0.028). Only the 
trials with CLIC1-R29A produced a value significantly different 
from the others (**p<0.01 vs. native CHO; ***p<0.001 vs. CLIC1 
wt and K37A, one-way ANOVA, followed by Tukey test). E-F) 
Currents from transfected CLIC1 constructs are functionally 
identified using anti-FLAG antibody acting as current blocker 
(see text). Both CLIC1 wt- (E) and R29A-transfected cells (F) 
show partial inhibition of membrane current by anti-FLAG 
antibody while the remaining current, representing endogenous 
CLIC1, was blocked by both metformin (10mM) and IAA94 
(100µM). G-H) Metformin induces a total membrane current 
knockdown in CLIC1 wt-transfected cells, without a further 
decrease caused by anti-FLAG antibody or IAA94 (G). In R29A-
expressing cells, metformin only partially blocks the current, 
which is fully inhibited by anti-FLAG antibody or IAA94 (H). 
I) Summary box-plots demonstrating that in CLIC1 R29A-
transfected cells a consistent part of the current is insensitive 
to metformin (Met). Mean Imet/IIAA94 ratios are 0.84±0.02 (n=3), 
0.76±0.08 (n=5), 0.52±0.07 (n=5) for native, transfected wt, and 
R29A mutant CLIC1, respectively. The current ratio in R29A 
transfected cells is statistically different from both native and 
CLIC1 wt-transfected cells. Further perfusion with anti-FLAG 





 ratio of 0.96±0.03 (n=3), 0.9±0.08 (n=5), 
0.87±0.05 (n=5) for native, wt and R29A CLIC1, respectively. 
In R29A-transfected cells metformin and anti-FLAG current 
inhibitions are statistically different. **p<0.01 and ***p<0.001 
(one way ANOVA followed by Tukey test).
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cycle progression) induced significant effects using lower 
in vitro metformin concentrations.
Metformin (200-1000µM) significantly inhibited 
CSC CLIC1 current during high frequency stimulation 
(1Hz, Fig. 6F and G). Furthermore, in accordance with 
data using U87 cells (Fig. 1G), prolonged treatment (up 
to 15 days) with low doses of metformin (10-300µM) 
significantly reduced CSC viability (Fig. 6H), displaying 
a precise inverse relationship between treatment duration 
and the concentration required to reduce CSC viability (i.e. 
10-30µM metformin are sufficient to elicit an effect after 
15 days, while 50 and 100µM required 10 and 7 days).
Experimental data suggest that the pore formed 
by CLIC1 has a single, 22 amino acids, transmembrane 
(TM) domain [29, 30, 35, 42, 47]. FRET data [42, 47] 
showed that TM segment forms an amphipathic α-helix 
where the only charged residues are Arg29 and Lys37. 
CLIC1 channel conformation is likely to be an oligomer 
of 7±1 monomers [42], similar to viroporin, formed by 
oligomerization of a single TM helix [48, 49], in which 
multiple copies (7±1) of Arg29 and Lys37 line the anion 
path. Arg29 is likely to be near the mouth of the pore 
at the cell surface, while Lys37 is in the middle of the 
TM region. Consistent with this model, R29A and K37A 
mutations alter CLIC1 biophysical parameters [41]: Arg29 
destabilizes the closed state of the channel and the R29A 
mutation results in a closed channel that only opens at 
positive membrane potential (away from the chloride 
reversal potential) [41]. Arg29 and/or Lys37 may therefore 
form part of the metformin binding site [35, 42]. Thus, we 
substituted each of them with alanine (R29A and K37A) 
[41], and measured metformin’s effects on CLIC1 currents 
in transfected CHO cells.
Metformin significantly inhibited membrane current 
in CLIC1 wt and K37A-transfected cells (Fig. 7A and D), 
but only partially in R29A-transfected cells (Fig. 7B). 
Conversely, similar IAA94 dose-response curves were 
observed in CLIC1 wt- and R29A-expressing cells (Fig. 
7C).
CLIC1 current in transfected CHO cells derives 
from a mixture of endogenous and transfected proteins. 
The current induced by the transfected protein is 
easily distinguishable from the endogenous one, since 
transfected channels are FLAG-tagged, and anti-FLAG 
antibody acts as channel blocker [29, 31]. Both wt- and 
R29A-expressing cells showed part of IAA94-sensitive 
current blocked by anti-FLAG antibody (Fig. 7E and 
F). Metformin completely abolished IAA94-sensitive 
membrane current in CLIC1-wt cells, with no further 
decrease observed in presence of the anti-FLAG antibody 
(Fig. 7G). Conversely, in R29A-transfected cells, after 
partial current inhibition by metformin, anti-FLAG 
antibody further decreased membrane current (Fig. 
7H). Average results (reported in Fig. 7I) support R29 
requirement for metformin inhibition of CLIC1. 
Outside-out single-channel experiments further 
confirmed that metformin directly acts on CLIC1 wt 
from the external side (Fig. 8A) but failed to shut-down 
single channels in CLIC1 R29A-transfected cells (Fig. 
8B). Accordingly, metformin was unable to inhibit CLIC1 
single channel current in inside-out trials (Fig. 8C). 
DISCUSSION
Drug repositioning represents a growing field in 
pharmacology research, opening in the last few years, 
unexpected, yet promising, novel approaches in particular 
for anti-cancer purposes [6, 50-53]
The crucial message coming out from our 
study is the identification of a molecular target for the 
antiproliferative activity of metformin in human GBM 
CSCs. Recently, several studies reported the in vitro and 
in vivo efficacy of metformin as antitumoral agent for 
most human tumors, including GBM [17, 18], showing its 
efficacy in reducing proliferation, survival, clonogenicity 
and in vivo tumorigenicity of CSC subpopulations. While 
these studies opened the way to ongoing clinical trials [2, 
54], in most cases, they did not address two central issues: 
Fig. 8: Molecular characterization of CLIC1 activity 
modulation by metformin A) Outside-out single channel 
experiments in native CHO cells show that anti-FLAG antibody 
does not inhibit CLIC1 current, differently from metformin 
(10mM) that closes the channel (single wt channel in control 
conditions Popen= 0.2±0.01, n=3 total of 6 minutes continuous 
recording). B) CLIC1 R29A, transfected in CHO cells, is 
insensitive to metformin, but it is promptly blocked by anti-
FLAG antibody (single R29A channel in control conditions 
Popen=0.21±0.008, n=3 total of 7 minutes continuous recording). 
C) Inside-out single channel experiments show that metformin 
fails to inhibit CLIC1 channel opening after more than 30 
seconds of continuous recording (single wt channel in control 
conditions Popen= 0.26±0.02, n=3 total of 10 minutes continuous 
recording).
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(i) the molecular mechanism by which metformin reduces 
tumor development and growth (considering that, at odds 
with the initial reports, most studies are now showing that 
AMPK activation is not the main player in this effect [19-
21]), and (ii) the mechanisms for metformin selectivity 
towards cancer cells, a rather unique characteristic for 
antitumoral drugs, but also demonstrated by the absence 
of significant toxicity of metformin when chronically used 
in diabetic patients.
The goal of our study was to provide answers to 
these questions, using CSC cultures, a reliable in vitro 
model of human GBM [38]. We propose CLIC1, a 
transiently active chloride channel previously identified as 
a requirement for GBM growth in vivo and in vitro [32], 
to be the molecular target of metformin activity. We show 
that metformin targets CLIC1 “functional expression” only 
when the protein translocates to the plasma-membrane 
where it acts as chloride conductive pore to allow the G1-S 
transition of the cells. Conversely, neither metformin nor 
IAA94 (a selective CLIC1 inhibitor) reduce proliferation 
of differentiated GBM cells or ucMSCs, in which CLIC1 
is similarly expressed but confined to the cytosol in an 
inactive conformation. Thus, the different activity and 
availability of CLIC1 as active chloride channel in 
normal and tumoral cells, dictates the strict selectivity of 
metformin towards CSCs. The specificity of metformin’s 
effects is corroborated by the observation that in diabetic 
patients and in experimental studies, chronic metformin 
treatment is not toxic to normal stem cells [55, 56], in 
contrast with mTOR inhibitors [55]. The observations that 
CLIC1 chloride current is essential for human GBM CSC 
proliferation [32] and that metformin preferentially affects 
CSC viability [17] support this assumption.
The transient functional activation of CLIC1 during 
mitosis in CSCs allows metformin to act as a selective 
CLIC1 inhibitor to slow-down cell cycle progression. 
Importantly, metformin time-dependent efficacy 
highlighted in this study might reconcile the different 
concentrations required to affect tumor proliferation in 
vitro and in vivo, with prolonged in vivo treatments likely 
being effective also with lower, clinically reachable, 
metformin concentrations. Moreover, the experiments 
using CLIC1 mutants, here reported, provided clues for 
the mechanism of the metformin-CLIC1 interaction. We 
demonstrate that metformin interacts with CLIC1 from 
the external side of the membrane at the amino terminus 
of the channel, presumably near the side chain of Arg29, 
which is responsible for destabilizing the closed state of 
the channel. These data allowed us to build a conceptual 
model for metformin’s action. Arg29 is likely to be near 
the anion path proximal to the extracellular surface. As it 
destabilizes the closed state of the channel, it could interact 
with a polar portion of the channel via its guanidinium 
moiety (Fig. 9A). Using its double guanidinium group, 
metformin may displace the side chain of Arg29 from 
this polar pocket, stabilizing the closed state and possibly 
obstructing the channel pore displacing the large arginine 
side chain (Fig. 9B). Metformin can only access this polar 
Fig. 9: Modelling of metformin-CLIC1 interaction. Schematic representation showing a possible mechanism of metformin’s inhibition 
of CLIC1 wt, while it has no effect on R29A mutant. A) In the closed state of CLIC1 wt, the side chain of Arg29 makes an interaction that 
destabilizes the closed state. This facilitates the opening of the channel near the chloride reversal potential. B) Metformin displaces the 
guanidinium moiety of Arg29, stabilizing the closed state. In addition, the displaced Arg29 side chain may obstruct the channel pore. C) 
In the R29A mutant, the closed state is stable near the chloride reversal potential, as there is no Arg29 side chain to make the destabilizing 
interaction as it is replaced by Ala29. D) Metformin is free to bind to the guanidinium site in R29A, as it is unoccupied. It has no effect on 
channel opening at high membrane potentials.
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site from the outside of the cell, as the binding site is near 
to the cell surface, given the position of Arg29 in the TM 
segment (consistent with the lack of effects in inside-out 
electrophysiology experiments). In contrast, CLIC1-
R29A, lacking Arg29 side chain, displays a more stable 
closed state, only opening at high membrane potential 
(Fig. 9C). The polar binding pocket (normally occupied 
by the guanidinium moiety of Arg29) is exposed and free 
to bind metformin (Fig. 9D). However, metformin binding 
has no effect on the electrophysiological properties of the 
Arg29-lacking mutant, as there is no arginine side chain to 
displace to cause channel inhibition. 
The observation that metformin effects in GBM 
CSCs may occur through an interaction on CLIC1 
Arg29 from the external side on cell membrane (see 
single channel recordings reported in Fig 8C) suggests 
that metformin antiproliferative activity in GBM CSCs 
is, at least partially, independent from its intracellular 
accumulation. However, comparing the effects of 
metformin and IAA94 (a “pure” CLIC1 inhibitor) some 
differences in efficacy and cell sensitivity are apparent in 
GBM cells (see cell viability and cell cycle data). This 
discrepancy highlights the possibility that additional 
cellular effects could be induced by metformin but not by 
IAA94. In fact, although several of the previously reported 
effects of metformin in cancer cells could be reconciled 
with the cell cycle regulation induced by CLIC1 
inhibition (i.e. modulation of kinase systems that control 
proliferation and/or survival [17, 22, 24], or the activation 
of transcription factors [26, 27]), recent data also reported 
a direct effect of this drug on complex I and oxidative 
phosphorylation, which, besides being responsible 
for its metabolic effects, could also interfere with cell 
proliferation [54, 57]. In particular, due to the avid glucose 
consumption as energy source for cancer cells, metformin 
antiproliferative effects were also reported to be mediated 
by alteration of cancer cell glucose metabolism via a 
direct inhibition of hexokinase II and its dissociation from 
mitochondria, to form an inactive cytosolic complex with 
metformin [58, 59]. As a consequence, glucose availability 
may also modulate cancer cell sensitivity to metformin 
[60, 61]. Thus, both metabolic (glucose metabolism) and 
transductional (CLIC1 inhibition) effects may account for 
synergistic antiproliferative effects of metformin.
The intracellular cascade activated by CLIC1 (and 
inhibited by metformin) responsible for CSC proliferation 
is still to be elucidated. From previous studies several 
possibilities could be considered including an oxidative 
environment generated on a rapid time-scale, which 
facilitates the progression of mitosis [43], CLIC1 
interaction with the cytoskeleton [62] and regulation of 
cell volume [63], which may ultimately affect cell viability 
via intracellular kinases [17].
In conclusion, metformin, whose ability to cross the 
blood-brain barrier was reported [18, 64], could represent 
a valuable therapeutic tool for GBM, due to its negligible 
side-effects, easy delivery, and low cost. Future clinical 
trials are required to definitely demonstrate metformin 
in vivo efficacy, although its time-dependent, low dose 
efficacy represents a good starting point to translate 
these results to the clinics. In addition, CLIC1 is a novel 
pharmacological target for newly designed drugs due 
to its accessibility from outside the cell and transient 
appearance in the membrane only during deregulated cell 
cycle progression.
MATERIALS AND METHODS 
Reagents and antibodies
Metformin (1,1-dimethylbiguanide-hydrochloride) 
and IAA94 (indanyloxyacetic acid 94) were from Sigma-
Aldrich (Milano, Italy). 
Antibodies: anti-CLIC1, Santa Cruz (Dallas, USA); 
anti-GFAP, anti-Nestin, and anti-N cadherin, Abcam 
(Cambridge, UK); anti-α-tubulin, anti-β-III tubulin, 
anti-FLAG M2-Cy3 and anti-FLAG M2, Sigma-Aldrich 
(Milano, Italy); anti-Olig2 and anti-Sox2, Millipore 
(Vimodrone, Italy); anti-Rb, BD Biosciences (Milano, 
Italy); Alexa Fluor 488 anti-mouse and Alexa Fluor 546 
anti-phalloidin, Invitrogen (Carlsbad CA, USA); DyLight 
459-goat anti-rabbit IgG, Jackson Immunoresearch (West 
Grove, USA). 
Human GBM CSC and ucMSC cultures
GBM CSC cultures were obtained from 2 females 
and 1 male patients (67, 40 and 71 years old, respectively) 
and coded as GBM1, GBM2, GBM3. Post-surgical 
samples were used after patients’ informed consent and 
Institutional Ethical Committee (IEC) approval. All 
patients underwent surgery at Neurosurgery Department 
(IRCCS-AOU San Martino-IST) and had not received 
therapy prior to the intervention. Specimens were 
histologically classified as GBM grade IV (WHO 
classification). 
CSCs, isolated as described [65, 66], were grown 
in stem cell-permissive medium enriched with 10ng/
ml human bFGF and 20ng/ml human EGF [39]. Sphere 
formation occurred within 2 weeks of culture (Fig. S3). 
CSCs were also grown as monolayer on growth factor-
reduced Matrigel coating (BD Biosciences), allowing 
easier evaluation of viability experiments without affecting 
stem cell features [65]. Validation of CSC properties of 
the cultures (i.e. self-renewal capacity, stem cell marker 
expression, multipotency, and tumorigenicity), was 
performed as described [17](see Fig. S3). Tumorigenicity 
was assessed in 6-8-week-old NOD-SCID mice (Charles 
River, Calco, Italy) (Fig. S3D) after IRCCS-AOU San 
Martino-IST (Genova, Italy) IACUC approval.
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Human umbilical cords were obtained after 
caesarean section at Obstetrics and Gynaecology 
Department of International Evangelical Hospital 
(Genova, Italy), following informed consent and approval 
by IEC. After vessel removal, cords were treated with 
collagenase (0.5µg/ml) to expose Wharton jelly and obtain 
single cells. Cells were grown in MesenPRO RS basal 
medium+Supplement (Life Technologies, Milano, Italy) 
after flow cytometry phenotypical characterization (MSC 
Phenotyping Kit, Miltenyi Biotec). Briefly, more than 95% 
ucMSCs were negative for hematopoietic antigens (CD45, 
CD34, CD14) and MHC class-II, and showed expression 
of CD73, CD105, CD90, CD29, and MHC class I. After 
incubation in selective media, ucMSCs differentiate into 
osteocytic, chondrocytic, and adipocytic lineages.
Cell lines and transfections
U87-MG and Chinese Hamster Ovary-K1 (CHO) 
were from Interlab Cell Line Collection (ICLC, Genova, 
Italy) and grown following standard conditions. Both 
cell lines were validated by ICLC. CLIC1 wt, R29A, and 
K37A mutants, tagged with FLAG peptide, were stably 
expressed in CHO cells using FuGENE Reagent (Roche, 
Basel, Switzerland) [30]. 
Electrophysiology
Patch electrodes (GB150F-8P with filament, Science 
Products) were pulled from hard borosilicate glass 
on a Brown-Flaming P-87 puller (Sutter Instruments, 
Novato, USA) and fire-polished to a tip diameter of 
1-1.5µm and an electrical resistance of 5-7 MΩ. Patch-
clamp electrophysiology was performed in whole cell, 
perforated-patch whole cell, and single channel outside-
out and inside-out configurations, as reported [32]. Single 
channel experiments were performed as previously 
described [41].
Cell proliferation assays
Mitochondrial function, as index of cell 
viability, was evaluated by measuring the reduction of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT, Sigma-Aldrich) as reported [67]. 
DNA synthesis was evaluated by the measurement 
of 5-bromo-2’-deoxyuridine (BrdU) incorporation in 
replicating DNA (Cell proliferation ELISA, Roche), 
following the manufacturer’s instructions.
For cell cycle analysis, cells were synchronised 
by growth factor starvation (60 hours), or nocodazole 
treatment (overnight incubation with nocodazole (50ng/
mL)-cytochalasin B (25ng/mL), in DMEM). Randomly 
cycling and synchronised cells were treated in stem cell-
permissive medium [39], and cell cycle analysis performed 
by flow cytometry (FACScalibur, BD Bioscience) with 
propidium iodide DNA staining [68].
Gene silencing
Short hairpins mRNA specific for human CLIC1 
(5’-GATGATGAGGAGATCGAGCTC-3’) and firefly 
luciferase (5’-CGTACGCGGAATACTTCGA-3’) were 
cloned into the XhoI/HpaI sites of the pLentiLox 3.7 
lentiviral vector [32] and stably expressed in GBM CSCs. 
Western blot
Whole cell lysates were obtained using a 
buffer containing 1% Igepal, 20 mM Tris-HCl, pH 
8, 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 
mM phenylmethylsulfonyl fluoride, 1 mM sodium 
orthovanadate, 10 mM NaF (all from Sigma-Aldrich), 
and the “Complete” protease inhibitor mixture (Roche) 
for 10 min at 4°C and proteins quantified using the 
Bradford assay (Bio-Rad Laboratories, Segrate MI, Italy). 
Membrane/cytoplasm fractions were obtained using the 
“Membrane protein extraction kit” (Thermo Scientific), 
following the manufacturer’s instructions. For Western 
blot experiments, proteins (20-60 μg) were resuspended 
in Laemmli buffer (2% SDS, 62.5 mM Tris, pH 6.8, 
0.01% bromophenol blue, 1.43 mM β-mercaptoethanol, 
0.1% glycerol), subjected to 10-12.5% SDS-PAGE, 
electroblotted onto polyvinylidene difluoride membrane 
(Bio-Rad Laboratories) and probed with specific 
antibodies. Immunocomplexes were detected using a 
chemiluminescence system (Immobilon, Millipore), and 
the ChemiDoc XRS apparatus (Bio-Rad Laboratories), as 
reported [69].
Statistical Analysis
All experiments were repeated at least twice 
(quantitative data were collected from experiments 
performed in triplicate or quadruplicate), and expressed 
as mean ± s.e.m. Statistical analyses and EC
50
 values, 
calculated using nonlinear regression curve fit analysis 
selecting the log(drug) vs. response-variable slope (four 
parameters) equation were done using Prism version 5.02 
(GraphPad San Diego CA, USA). Statistical significance 
between groups was assessed by t-test (unpaired, two-
tailed) or one-way ANOVA followed by Dunnett’s 
multiple comparison post-test or Tukey tests. Statistical 
significance was established at p values <0.05.
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